Spots Global Cancer Trial Database for mirvetuximab soravtansine
Every month we try and update this database with for mirvetuximab soravtansine cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer | NCT02996825 | Recurrent Breas... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Recurrent Uteri... Triple-Negative... | Gemcitabine Gemcitabine Hyd... Laboratory Biom... Mirvetuximab So... Pharmacological... | - | City of Hope Medical Center | |
| Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer | NCT03836157 | Endometrial Can... Endometrial Ade... Endometrial Ser... Endometrial Cle... | Mirvetuximab So... Bevacizumab | 18 Years - | University of Oklahoma | |
| First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Mirvetuximab Soravtansine in Adults With Ovarian Cancer and Other Folate Receptor 1 (FOLR1)-Positive Solid Tumors | NCT01609556 | Tumors | Mirvetuximab so... | 18 Years - | ImmunoGen, Inc. | |
| Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer | NCT02606305 | Epithelial Ovar... Primary Periton... Fallopian Tube ... | Mirvetuximab so... Bevacizumab Carboplatin Pegylated Lipos... Pembrolizumab | 18 Years - | ImmunoGen, Inc. | |
| Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer | NCT02996825 | Recurrent Breas... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Recurrent Uteri... Triple-Negative... | Gemcitabine Gemcitabine Hyd... Laboratory Biom... Mirvetuximab So... Pharmacological... | - | City of Hope Medical Center | |
| An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib | NCT05887609 | Ovary Cancer Peritoneal Canc... Fallopian Tube ... | Mirvetuximab So... Olaparib | 18 Years - 99 Years | University of Colorado, Denver | |
| Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer | NCT03552471 | BRCA1 Gene Muta... BRCA2 Gene Muta... Folate Receptor... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Recurrent Uteri... Recurrent Uteri... Recurrent Uteri... Platinum Resist... | Laboratory Biom... Mirvetuximab So... Pharmacokinetic... Rucaparib Camsy... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers (PICCOLO) | NCT05041257 | Ovarian Cancer Peritoneal Canc... Fallopian Tube ... | Mirvetuximab so... | 18 Years - | ImmunoGen, Inc. | |
| Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers (PICCOLO) | NCT05041257 | Ovarian Cancer Peritoneal Canc... Fallopian Tube ... | Mirvetuximab so... | 18 Years - | ImmunoGen, Inc. | |
| IMGN853 With Carboplatin in Second-line Treatment of FRα Expressing, Platinum-sensitive Epithelial Ovarian Cancer | NCT05456685 | High Grade Ovar... Primary Periton... Fallopian Tube ... | Mirvetuximab so... Carboplatin | 18 Years - | ImmunoGen, Inc. | |
| A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression | NCT04296890 | Epithelial Ovar... Peritoneal Canc... Fallopian Tube ... | Mirvetuximab So... | 18 Years - | ImmunoGen, Inc. | |
| A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression | NCT06365853 | Recurrent Ovari... Folate Receptor... | Mirvetuximab So... Lubricating Eye... Prednisolone ac... Brimonidine tar... | 18 Years - | ImmunoGen, Inc. | |
| Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer | NCT04274426 | Recurrent Epith... | Carboplatin Pegylated lipos... Gemcitabine Paclitaxel Mirvetuximab So... | 18 Years - | AGO Research GmbH | |
| Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer | NCT02996825 | Recurrent Breas... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Recurrent Uteri... Triple-Negative... | Gemcitabine Gemcitabine Hyd... Laboratory Biom... Mirvetuximab So... Pharmacological... | - | City of Hope Medical Center | |
| Mirvetuximab Soravtansine (IMG853) in Folate Receptor Alpha-expressing TNBC | NCT03045393 | Breast Cancer T... | Mirvetuximab So... | 18 Years - | Duke University | |
| A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression | NCT04296890 | Epithelial Ovar... Peritoneal Canc... Fallopian Tube ... | Mirvetuximab So... | 18 Years - | ImmunoGen, Inc. | |
| Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer | NCT03836157 | Endometrial Can... Endometrial Ade... Endometrial Ser... Endometrial Cle... | Mirvetuximab So... Bevacizumab | 18 Years - | University of Oklahoma | |
| Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer | NCT03552471 | BRCA1 Gene Muta... BRCA2 Gene Muta... Folate Receptor... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Recurrent Uteri... Recurrent Uteri... Recurrent Uteri... Platinum Resist... | Laboratory Biom... Mirvetuximab So... Pharmacokinetic... Rucaparib Camsy... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer | NCT02631876 | Epithelial Ovar... Primary Periton... Fallopian Tube ... Ovarian Cancer | Mirvetuximab so... Paclitaxel Pegylated lipos... Topotecan | 18 Years - | ImmunoGen, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
